24 min listen
A Biopharma Downturn or Return to Trend
FromThe Bio Report
ratings:
Length:
28 minutes
Released:
Apr 12, 2023
Format:
Podcast episode
Description
In 2022, investment in biopharmaceutical companies, pipeline activity, and the launch of novel medicines all dropped from the previous year. A new report from IQVIA’s Institute for Human Data Sciences argues the downturn, after two record-setting years, is a post pandemic return to longer-term trends. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about what happened to the biopharmaceutical sector in 2022, how to make sense of the data, and the shifting landscape in therapeutic and geographic investments.
Released:
Apr 12, 2023
Format:
Podcast episode
Titles in the series (100)
Biotech Investors Turn Their Eyes to Policy Matters: Wall Street doesn’t like uncertainty and there are a number of policy issues now brewing that threaten to create some uncertainty for the biotechnology industry. As the BIO Investor Forum kicks off in San Francisco October 20 and 21, bringing togethe... by The Bio Report